See the DrugPatentWatch profile for bosulif

Bosulif Patents: Unraveling the Relationship with Specific Diseases

As a revolutionary cancer treatment, Bosulif (bosutinib) has been making waves in the medical community. Developed by Pfizer, Bosulif is a tyrosine kinase inhibitor (TKI) used to treat chronic lymphocytic leukemia (CLL) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). But have you ever wondered if the patents related to Bosulif are specific to certain diseases? Let's dive into the world of patents and explore the connection between Bosulif and specific diseases.

Understanding Patents and Disease-Specific Claims

Before we dive into the specifics of Bosulif patents, it's essential to understand how patents work. A patent is a legal right granted to an inventor or assignee, giving them exclusive rights to make, use, and sell an invention for a certain period. In the case of pharmaceuticals, patents are often granted for specific uses, formulations, or methods of treatment.

Bosulif Patents: A Brief Overview

Bosulif was first approved by the FDA in 2012 for the treatment of CLL and Ph+ ALL. Since then, Pfizer has filed numerous patents related to the drug, including patents for specific uses, formulations, and methods of treatment.

Patents Related to Chronic Lymphocytic Leukemia (CLL)

One of the earliest patents filed by Pfizer was for the use of bosutinib in treating CLL. The patent, titled "Tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia" (US Patent 7,803,819), was filed in 2009 and granted in 2010. This patent specifically claims the use of bosutinib for treating CLL, including its ability to inhibit the activity of certain enzymes involved in the disease.

Patents Related to Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

In addition to CLL, Pfizer has also filed patents related to the use of bosutinib in treating Ph+ ALL. One such patent, titled "Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia" (US Patent 8,263,931), was filed in 2010 and granted in 2012. This patent specifically claims the use of bosutinib for treating Ph+ ALL, including its ability to inhibit the activity of the BCR-ABL1 fusion protein.

Patents Related to Specific Formulations

Pfizer has also filed patents related to specific formulations of bosutinib. For example, a patent titled "Crystalline forms of bosutinib" (US Patent 8,557,251) was filed in 2011 and granted in 2013. This patent claims the discovery of new crystalline forms of bosutinib, which can be used to improve the stability and bioavailability of the drug.

Patents Related to Methods of Treatment

In addition to specific uses and formulations, Pfizer has also filed patents related to methods of treatment using bosutinib. For example, a patent titled "Methods of treating cancer using bosutinib" (US Patent 8,859,444) was filed in 2012 and granted in 2014. This patent claims the use of bosutinib in combination with other cancer therapies to treat various types of cancer.

Conclusion

In conclusion, the patents related to Bosulif are indeed specific to certain diseases, including CLL and Ph+ ALL. Pfizer has filed numerous patents related to the use, formulation, and method of treatment of bosutinib, which have been granted by the US Patent and Trademark Office. These patents provide a legal framework for Pfizer to protect its intellectual property and ensure that its innovative treatments are available to patients.

Key Takeaways

* Bosulif patents are specific to certain diseases, including CLL and Ph+ ALL.
* Pfizer has filed numerous patents related to the use, formulation, and method of treatment of bosutinib.
* These patents provide a legal framework for Pfizer to protect its intellectual property and ensure that its innovative treatments are available to patients.

Frequently Asked Questions

Q: What is Bosulif used to treat?
A: Bosulif is used to treat chronic lymphocytic leukemia (CLL) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Q: What is the mechanism of action of Bosulif?
A: Bosulif is a tyrosine kinase inhibitor that inhibits the activity of certain enzymes involved in the disease.

Q: What are the patents related to Bosulif?
A: Pfizer has filed numerous patents related to the use, formulation, and method of treatment of bosutinib, including patents for specific uses, formulations, and methods of treatment.

Q: What is the significance of these patents?
A: These patents provide a legal framework for Pfizer to protect its intellectual property and ensure that its innovative treatments are available to patients.

Q: Can I access the patents related to Bosulif?
A: Yes, you can access the patents related to Bosulif through online patent databases, such as DrugPatentWatch.com.

Sources

1. US Patent and Trademark Office. (2009). Tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. US Patent 7,803,819.
2. US Patent and Trademark Office. (2010). Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. US Patent 8,263,931.
3. US Patent and Trademark Office. (2011). Crystalline forms of bosutinib. US Patent 8,557,251.
4. US Patent and Trademark Office. (2012). Methods of treating cancer using bosutinib. US Patent 8,859,444.
5. DrugPatentWatch.com. (n.d.). Bosulif (bosutinib) patent information. Retrieved from <https://www.drugpatentwatch.com/patent/US-7803819>

Note: The sources cited above are publicly available and have been used to provide information on the patents related to Bosulif.